Amgen Says FDA Flouted Own Rules In Calcium Drug Row
Amgen told the D.C. Circuit on Tuesday that the U.S. Food and Drug Administration flouted its statutory mandates by denying the drug giant pediatric exclusivity for its lucrative calcium-control drug Sensipar,...To view the full article, register now.
Already a subscriber? Click here to view full article